Journal article
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study
Abstract
BACKGROUND: The XANTUS study (NCT01606995) demonstrated low rates of stroke and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical practice for the prevention of thromboembolic events (N = 6784).
HYPOTHESIS: Because previous real-world studies have not reported gender-dependent responses to rivaroxaban treatment, this sub-analysis of the XANTUS study investigated the effect of gender on outcomes.
Authors
Camm AJ; Amarenco P; Haas S; Bach M; Kirchhof P; Kuhls S; Lambelet M; Turpie AGG; Investigators X
Journal
Clinical Cardiology, Vol. 43, No. 12, pp. 1405–1413
Publisher
Wiley
Publication Date
12 2020
DOI
10.1002/clc.23452
ISSN
0160-9289